244 related articles for article (PubMed ID: 33270989)
1. Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit.
Lu J; Xu BB; Xue Z; Xie JW; Zheng CH; Huang CM; Li P
Cancer Med; 2021 Jan; 10(1):34-44. PubMed ID: 33270989
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of postoperative C-reactive protein elevation versus complication occurrence: a multicenter validation study.
Kurokawa Y; Yamashita K; Kawabata R; Fujita J; Imamura H; Takeno A; Takahashi T; Yamasaki M; Eguchi H; Doki Y
Gastric Cancer; 2020 Sep; 23(5):937-943. PubMed ID: 32314097
[TBL] [Abstract][Full Text] [Related]
3. Which is a more reliable indicator of survival after gastric cancer surgery: Postoperative complication occurrence or C-reactive protein elevation?
Saito T; Kurokawa Y; Miyazaki Y; Makino T; Takahashi T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
J Surg Oncol; 2015 Dec; 112(8):894-9. PubMed ID: 26458724
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of postoperative systemic inflammatory response in patients with stage II/III gastric cancer.
Kuroda K; Toyokawa T; Miki Y; Yoshii M; Tamura T; Tanaka H; Lee S; Muguruma K; Yashiro M; Ohira M
Sci Rep; 2022 Feb; 12(1):3025. PubMed ID: 35194147
[TBL] [Abstract][Full Text] [Related]
5. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial.
Lu J; Xu BB; Zheng ZF; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Zheng CH; Huang CM; Li P
Gastric Cancer; 2019 May; 22(3):536-545. PubMed ID: 30377862
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of Preoperative Plasma Fibrinogen Versus Other Prognostic Markers for Predicting Gastric Cancer Recurrence.
Yamamoto M; Kurokawa Y; Miyazaki Y; Makino T; Takahashi T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
World J Surg; 2016 Aug; 40(8):1904-9. PubMed ID: 26969673
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data.
Xu BB; Lu J; Zheng ZF; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Zheng CH; Huang CM; Li P
Gastric Cancer; 2019 Sep; 22(5):1016-1028. PubMed ID: 30739259
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Perioperative C-Reactive Protein in Resected Non-Small Cell Lung Cancer.
Okada S; Shimomura M; Tsunezuka H; Teramukai S; Ishihara S; Shimada J; Inoue M
Semin Thorac Cardiovasc Surg; 2020 Winter; 32(4):1046-1055. PubMed ID: 32437868
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Serum C-Reactive Protein Level Predicts Long-term Outcomes in Stage I Gastric Cancer.
Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
J Surg Res; 2019 Oct; 242():323-331. PubMed ID: 31129241
[TBL] [Abstract][Full Text] [Related]
10. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.
Nishibeppu K; Komatsu S; Ichikawa D; Imamura T; Kosuga T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Otsuji E
BMC Cancer; 2018 Jan; 18(1):108. PubMed ID: 29382310
[TBL] [Abstract][Full Text] [Related]
11. Elevated high-sensitivity C-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence.
Woo Y; Hyung WJ; Obama K; Kim HI; Pak KH; Son T; Noh SH
J Surg Oncol; 2012 Mar; 105(4):405-9. PubMed ID: 22025360
[TBL] [Abstract][Full Text] [Related]
12. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer.
Kambara Y; Miyake H; Nagai H; Yoshioka Y; Shibata K; Asai S; Yuasa N
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1918-1924. PubMed ID: 32814681
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a prognostic nomogram for predicting early recurrence after curative resection of stage II/III gastric cancer.
Ma M; Xiao H; Li L; Yin X; Zhou H; Quan H; Ouyang Y; Huang G; Li X; Xiao H
World J Surg Oncol; 2019 Dec; 17(1):223. PubMed ID: 31856828
[TBL] [Abstract][Full Text] [Related]
14. Impact of visceral adipose tissue on compliance of adjuvant chemotherapy and relapse-free survival after gastrectomy for gastric cancer: A propensity score matching analysis.
Matsui R; Inaki N; Tsuji T
Clin Nutr; 2021 May; 40(5):2745-2753. PubMed ID: 33933740
[TBL] [Abstract][Full Text] [Related]
15. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer.
Kudou K; Saeki H; Nakashima Y; Kamori T; Kawazoe T; Haruta Y; Fujimoto Y; Matsuoka H; Sasaki S; Jogo T; Hirose K; Hu Q; Tsuda Y; Kimura K; Ando K; Oki E; Ikeda T; Maehara Y
J Gastroenterol Hepatol; 2019 Feb; 34(2):355-363. PubMed ID: 30119141
[TBL] [Abstract][Full Text] [Related]
17. [Preoperative C-reactive protein predicts recurrence after curative resection in advanced gastric cancer patients receiving postoperative adjuvant chemotherapy using S-1].
Shimizu T; Ishizuka M; Sakuraoka Y; Shiraki T; Abe A; Mori S; Iso Y; Takagi K; Aoki T; Kubota K
Nihon Shokakibyo Gakkai Zasshi; 2020; 117(2):150-156. PubMed ID: 32037360
[TBL] [Abstract][Full Text] [Related]
18. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.
Matsuoka H; Ando K; Hu Q; Zaitsu Y; Tsuda Y; Hisamatsu Y; Nakashima Y; Kimura Y; Oki E; Mori M
Int J Clin Oncol; 2020 Jul; 25(7):1318-1326. PubMed ID: 32279124
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of perioperative leukocyte count in resectable gastric cancer.
Chen XF; Qian J; Pei D; Zhou C; Røe OD; Zhu F; He SH; Qian YY; Zhou Y; Xu J; Xu J; Li X; Ping GQ; Liu YQ; Wang P; Guo RH; Shu YQ
World J Gastroenterol; 2016 Mar; 22(9):2818-27. PubMed ID: 26973420
[TBL] [Abstract][Full Text] [Related]
20. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
